Korean pharmaceutical firm Celltrion said on Tuesday that in an attempt to offset the risk of U.S. tariffs, it had become the preferred bidder to acquire a U.S. manufacturing factory from an unnamed ...

With more-than-satisfying phase III data in hand, Minneapolis-based Celcuity Inc. is eyeing an NDA submission in the fourth quarter of this year for gedatolisib (geda) in breast cancer. Shares of the ...

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

While U.S. government cost-cutting seems to be the Trump administration’s priority that consumes all others, some Republican ...

In a recently-issued Director Discretionary Denial decision, U.S. Patent and Trademark Office (USPTO) Acting Director Coke ...

Bayer's steady cash flows from healthcare and crop science products should enable the company to both reduce debt and service current debt levels. However, the high debt levels and slow near-term ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Biogen BIIB will report second-quarter 2025 results on July 31, before market open. In the last reported quarter, the company's earnings missed expectation by 7.4%. The Zacks Consensus Estimate for ...

In a major relief to Zydus Lifesciences, the Delhi High Court dismissed F. Hoffmann-La Roche's plea seeking disclosure of ...